Ph All clinical trials

Explore recruiting ph all clinical trials.

Recruiting ph all studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Ph All trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Olverembatinib Combined with Chemotherapy Versus Investigator’s Choice of TKI Combined with Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) (POLARIS-1)

Hungary, France, Romania, Czechia, Italy, Spain +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

International phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones

Germany, Sweden, Denmark, Italy, Austria, Czechia +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Randomized, Open-Label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination with Reduced-Intensity Chemotherapy, in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Spain, Italy, Austria, Poland, Greece, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Ponatinib for the management of minimal residual disease (MRD) and hematologic relapsein adult Ph+ acute lymphoblastic leukemia (Ph+ ALL) patients.ALL2620

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

An open label, multi-center asciminib roll-over study to assess long-term safety in patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment

Czechia, Germany, Portugal, Spain, Poland, Denmark +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Newly Diagnosed Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL). Sequential Treatment with Ponatinib and the Bispecific Monoclonal Antibody Blinatumomab vs Chemotherapy and Imatinib. ALL2820

Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

Ph All trials by city

Ph All in Toronto Ph All in Vancouver Ph All in Montreal Ph All in Calgary Ph All in Edmonton Ph All in Ottawa Ph All in Winnipeg Ph All in Quebec City Ph All in Hamilton Ph All in Kitchener Ph All in London Ph All in Halifax Ph All in New York Ph All in Los Angeles Ph All in Chicago Ph All in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease